SuperworthContineum Therapeutics EPS CTNM
Diluted earnings per share by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$0.40
- Fiscal year 2024
- −$4.90
Contineum Therapeutics' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$0.40.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2024 | −$4.90 | n/a |
| FY2023 | −$4.48 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.40 | n/a | n/a | |
| Q1 FY26 | −$0.39 | n/a | n/a | |
| Q2 FY25 | −$0.62 | n/a | −$2.20 | |
| Q1 FY25 | −$0.62 | n/a | −$1.97 | |
| Q4 FY24 | −$0.56 | n/a | −$4.90 | |
| Q3 FY24 | −$0.40 | n/a | −$4.85 | |
| Q2 FY24 | −$0.39 | −146% | −$7.14 | |
| Q1 FY24 | −$3.55 | n/a | −$5.91 | |
| Q4 FY23 | −$0.51 | n/a | −$4.48 | |
| Q3 FY23 | −$2.69 | n/a | n/a | |
| Q2 FY23 | $0.84 | n/a | n/a | |
| Q1 FY23 | −$2.12 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Contineum Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CTNMContineum Therapeutics | n/m | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| Peer median | $0.97 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Contineum Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.